(40 days)
Trinity Biotech Captia EBV EA-D IgG
Not Found
No
The summary describes a standard enzyme immunoassay (EIA) for detecting antibodies. There is no mention of AI, ML, or any computational analysis beyond standard statistical calculations for performance metrics.
No.
This device is an in vitro diagnostic (IVD) test used to detect antibodies for diagnostic purposes, not to treat a disease or condition.
Yes
This device is designed for the qualitative detection of human IgG antibodies to Epstein-Barr virus early antigen diffuse (EA-D) in human serum, to be used as an "aid in the laboratory diagnosis of EBV infectious mononucleosis." This statement directly indicates its intended use as a diagnostic tool.
No
The device is an in vitro diagnostic (IVD) test kit that uses a solid-phase enzyme immunoassay (EIA) performed in microwells to detect antibodies in human serum. This involves physical reagents and laboratory procedures, not just software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states: "For In Vitro Diagnostic Use Only."
- Purpose: The device is designed to detect human IgG antibodies in human serum, which is a biological sample taken from the body. This analysis is performed in vitro (outside the body) to aid in the diagnosis of a disease (EBV infectious mononucleosis).
- Device Description: The description details a "solid-phase enzyme immunoassay (EIA)," which is a common method used in IVD tests to detect specific substances in biological samples.
- Performance Studies: The document describes clinical performance studies, cross-reactivity testing, and precision studies, all of which are standard evaluations for IVD devices to demonstrate their accuracy and reliability for diagnostic purposes.
- Predicate Device: The mention of a "Predicate Device" (Trinity Biotech Captia EBV EA-D IgG) indicates that this device is being compared to an already cleared IVD device, a common practice in the regulatory pathway for new IVDs.
All these elements clearly align with the definition and characteristics of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The SeraQuest EBV EA-D IgG test is for the qualitative detection of human IgG antibodies to Epstein-Barr virus early antigen diffuse (EA-D) in human serum by enzyme immunoassay. This assay uses a 28 kd E. coli expressed recombinant Epstein-Barr virus early antigen. When performed in conjunction with other EBV serological tests, this assay can be used as an aid in the laboratory diagnosis of EBV infectious mononumucleosis in patients with signs and symptoms of EBV infectious mononucleosis. For In Vitro Diagnostic Use Only.
Assay performance characteristics have not been established for neonatal, immunocompromised populations, cord blood, infants or pre-transplant patients. Assay performance characteristics have not been established for the diagnosis of nasopharyngeal carcinoma, Burkitt's lymphoma, and other EBV-associated lymphomas.
Product codes
LSE
Device Description
The SeraQuest EBV EA-D IgG Test is a solid-phase enzyme immunoassay (EIA), which is performed in microwells, at room temperature, in three thirty minute incubations. It has been developed to detect IgG antibodies which are directed against EBV Early Antigen D (EA-D), in human serum.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Assay performance characteristics have not been established for neonatal, immunocompromised populations, cord blood, infants or pre-transplant patients.
Intended User / Care Setting
Laboratory diagnosis
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A total of 542 serum samples for which EBV serology tests were ordered was tested at 3 U.S. clinical testing sites. Of the 542 specimens, 477 were prospectively collected and prospectively tested specimens, and 65 were prospectively collected but retrospectively tested specimens to supplement the prospective study data. Of the 65 prospectively collected but retrospectively tested specimens, 50 were acute specimens and 15 were EBV seronegative specimens characterized by reference EBV serology assays for EBV VCA IgG, EBV VCA IgM, and EBV EBNA-1 IgG, Based upon the results of the three reference EBV serology tests, the specimens were categorized into one of four EBV serological state groups as indicated in Table 1 below.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical Performance Comparison:
542 serum samples (477 prospectively collected and tested; 65 prospectively collected and retrospectively tested) from 3 U.S. clinical testing sites were evaluated.
The SeraQuest EBV EA-D IgG Test was compared against another commercially available EBV EA-D IgG ELISA test. Specimens were categorized into EBV serological states (Acute, EBV seronegative, Past Infection, Indeterminate) based on reference EBV serology assays for EBV VCA IgG, EBV VCA IgM, and EBV EBNA-1 IgG.
Key Results (SeraQuest EBV EA-D IgG Test vs. Comparator Assay):
Overall for 477 Prospectively Collected and Tested Samples:
- Positive Agreement: 62.6% (95% CI: 55.0-70.2)
- Negative Agreement: 81.3% (95% CI: 76.9-85.6)
Overall for 65 Prospectively Collected but Retrospectively Tested Samples:
- Positive Agreement: 86.5% (95% CI: 71.2-95.5)
- Negative Agreement: 70.4% (95% CI: 49.8-86.2)
Agreement of the SeraQuest EBV EA-D IgG Test relative to the EBV Serological Classification:
For 477 Prospectively Collected and Tested Specimens:
- Positive Agreement (Acute Infection): 17/31 (54.8%, 95% CI: 36.0-72.7)
- Negative Agreement (EBV Seronegative): 47/60 (78.3%, 95% CI: 65.8-87.9)
- Negative Agreement (Past Infection): 187/311 (60.1%, 95% CI: 54.7-65.6)
For 65 Prospectively Collected and Retrospectively Tested Specimens:
- Positive Agreement (Acute Infection): 35/50 (70.0%, 95% CI: 55.4-82.1)
- Negative Agreement (No Infection): 13/15 (86.7%, 95% CI: 59.5-98.3)
Cross-reactivity:
316 total samples positive for various infectious diseases, heterophilic antibodies, autoimmune antibodies and antibodies against other EBV markers were tested.
Result: 0/316 positive or equivocal results.
Potential Interfering Substances:
The effects of icterus, hemolysis, hyperglycemia, hyperlipidemia, and hyperproteinemia were examined. No significant interference was observed with up to eight times the normal physiological concentration of each potential interfering substance. No false negative results for weak positive specimens and no false positive results for negative specimens.
Precision/Reproducibility:
A panel of 6 members (1 negative, 1 high negative to equivocal, 4 positive) prepared from patient samples, plus positive and negative controls. Tested 3 times a day for 3 days at 3 US testing sites (27 replicates per member/control).
Intra-assay, inter-assay, and between-site reproducibility, SD, and %CV calculated. Examples of %CV for total variability:
- SeraQuest Positive Serum Control: 8.0%
- SeraQuest Negative Serum Control: 8.4%
- High negative to equivocal (Near C.O.): 4.2%
- Negative: 14.0%
- Positive 1: 10.5%
- Positive 2: 7.9%
- Positive 3: 8.9%
- Positive 4: 9.2%
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found. Presented as Percent Agreement and Confidence Intervals.
Predicate Device(s)
Trinity Biotech Captia EBV EA-D IgG
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.3235 Epstein-Barr virus serological reagents.
(a)
Identification. Epstein-Barr virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to Epstein-Barr virus in serum. The identification aids in the diagnosis of Epstein-Barr virus infections and provides epidemiological information on diseases caused by these viruses. Epstein-Barr viruses are thought to cause infectious mononucleosis and have been associated with Burkitt's lymphoma (a tumor of the jaw in African children and young adults) and postnasal carcinoma (cancer).(b)
Classification. Class I (general controls).
0
ATTACHMENT 7 Quest International, Inc., 8127 NW 29th Street, Doral, FL 33122
Page No.
510(k) SUMMARY
Quest International, Inc.
8127 NW 29th Street
JUN - 8 2009
| | 6727 NW 25th Street
Doral, FL 33122 |
|------------------------|------------------------------------------------------------|
| Registration No. | 1061839 |
| Contact Person: | David J. Kiefer, Ph.D., |
| Telephone: | (305) 592-6991 |
| Telefax: | (305) 592-6834 |
| Manufacturing Site: | Same as above |
| Device: | SeraQuest® EBV EA-D IgG |
| Device Name: | Epstein-Barr virus serological reagents (21CFR § 866.3235) |
| Device Classification: | Class I (general controls) |
Description:
Applicant:
The SeraQuest EBV EA-D IgG Test is a solid-phase enzyme immunoassay (EIA), which is performed in microwells, at room temperature, in three thirty minute incubations. It has been developed to detect IgG antibodies which are directed against EBV Early Antigen D (EA-D), in human serum.
Principle:
Diluted samples are incubated in wells coated with EBV Early Antigen D. Antibodies directed against the antigen (if present) are immobilized in the wells. Residual sample is eliminated by washing and draining, and conjugate (enzyme-labeled antibodies to human IgG) is added and incubated. If IgG antibodies to EBV Early Antigen D are present, the conjugate will be immobilized in the wells. Residual conjugate is eliminated by washing and draining, and the enzyme substrate is added and incubated. In the presence of the enzyme, the substrate is converted to a yellow end-product which is read photometrically at 405 nm.
1
Intended Use:
The SeraQuest EBV EA-D IgG test is for the qualitative detection of human IgG antibodies to Epstein-Barr virus early antigen diffuse (EA-D) in human serum by enzyme immunoassay. This assay uses a 28 kd E. coli expressed recombinant Epstein-Barr virus early antigen. When performed in conjunction with other EBV serological tests, this assay can be used as an aid in the laboratory diagnosis of EBV infectious mononucleosis in patients with signs and symptoms of EBV infectious mononucleosis. For In Vitro Diagnostic Use Only.
Assay performance characteristics have not been established for neonatal, immunocompromised populations, cord blood, infants or pre-transplant patients. Assay performance characteristics have not been established for the diagnosis of nasopharyngeal carcinoma, Burkitt's lymphoma, and other EBV-associated lymphomas.
Predicate Device:
The SeraQuest® EBV EA-D IgG test is substantially equivalent in intended use and performance, to the Trinity Biotech Captia EBV EA-D IgG, Jamestown, NY.
Summary of technological characteristics:
| Characteristic | SeraQuest EBV EA-D IgG | Trinity Biotech EBV EA-D IgG |
|---|---|---|
| Description: | Enzyme Immunoassay | Enzyme Immunoassay |
| Intended Use: | The detection of IgG | |
| antibodies against EBV | ||
| EA-D | ||
| in human serum. | The detection of IgG | |
| antibodies against EBV | ||
| EA-D | ||
| in human serum. | ||
| Solid Phase: | Plastic Microwell | Plastic Microwell |
| Antigen : | Recombinant EA-D 28 kd | Recombinant EA-D 28 kd |
| Number of Incubation Periods: | Three | Four |
| Sample Dilution: | 1:51 | 1:21 |
| Sample Incubation | ||
| Duration: | 30 minutes | 20 minutes |
2
ATTACHMENT 7 Quest International, Inc., 8127 NW 29th Street, Doral, FL 33122 Page No.
서 대통령
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:
Page No
: . 197
: 上 ,在上一篇:
:
1999 - 1999 - 1999
.
.
:
..
: 上
...
: 上一篇:
| Incubation Temperature: | Room temperature | Room temperature |
|---|---|---|
| Ezyme-labeled Conjugate: | ||
| Antibody | Goat anti-human IgG | Goat anti-human IgG |
| Label | Alkaline phosphatase | Horseradish Peroxidase |
| Conjugate Volume: | 100 µl | 100 µl |
| Conjugate Incubation | ||
| Duration: | 30 minutes | 20 minutes |
| Substrate: | p-Nitrophenyl | |
| phosphate | TMB | |
| Subtrate Volume: | 100 µl | 100 µl |
| Substrate Incubation | ||
| Duration: | 30 minutes | 10 minutes |
| Stop Reagent: | 0.5 M Trisodium | |
| phosphate | 1M H2SO4,0.7M HCL | |
| Stop Reagent Volume: | 100 µl | 50 µl |
| Readout: | Spectrophotometric | Spectrophotometric |
3
Clinical Performance Comparison
Performance of the SeraQuest EBV EA-D IgG Test was evaluated against another commercially available EBV EA-D IgG ELISA test according to the EBV serological characterization of the specimens as determined by other EBV serological reagents. For purposes of classifying the EBV serological state, specimens were tested by reference EBV serology assays for EBV VCA IgG, EBV VCA IgM, and EBV EBNA-1 IgG. The EBV EA-D IgG result generated by the commercially available comparator EBV EA-D IgG ELISA test was not considered for purposes of characterizing the EBV serological state of the specimen. A total of 542 serum samples for which EBV serology tests were ordered was tested at 3 U.S. clinical testing sites. Of the 542 1 specimens, 477 were prospectively collected and prospectively tested specimens, and 65 were prospectively collected but retrospectively tested specimens to supplement the prospective study data. Of the 65 prospectively collected but retrospectively tested specimens, 50 were acute specimens and 15 were EBV seronegative specimens characterized by reference EBV serology assays for EBV VCA IgG, EBV VCA IgM, and EBV EBNA-1 IgG, Based upon the results of the three reference EBV serology tests, the specimens were categorized into one of four EBV serological state groups as indicated in Table 1 below.
| EBV
serological
state | Specimen Group | | EBV
VCA IgG | EBV
VCA
IgM | EBV
EBNA-1
IgG |
|-----------------------------|-----------------------------------------------------|-------------------------------------------------------|----------------|-------------------|----------------------|
| | Prospectively Collected and
Prospectively Tested | Prospectively Collected but
retrospectively Tested | | | |
| Acute | 31 | 50 | + | + | - |
| | | | - | + | - |
| EBV
seronegative | 60 | 15 | - | - | - |
| Past Infection | 311 | 0 | + | - | + |
| Indeterminate | 75 | 0 | - | - | + |
| | | | + | - | - |
Table 1: EBV serological state characterization
4
| 3 | |||||
|---|---|---|---|---|---|
| 1 | + | t | |||
| Carolina Comments of Children |
-
| + | + |
| Total | 477 | .
હક | ------------------------------------------------------------------------------ | | |
| | --------
. . | ALL CLAND | | | |
- reactive; - nonreactive;
Note: When a reference assay was equivocal, it was considered nonreactive (-). The characterization by antibody response profile was not compared with clinical data regarding presence, absence or status of disease.
Using Table 1 as a guideline, testing results were analyzed by the SeraQuest EBV EA-D IgG Test and corresponding comparative EBV EA-D IgG ELISA test according to the EBV serological characterization based on EBV serology reference assays results. For the purpose of percent agreement calculations, SeraQuest EBV EA-D IgG test equivocal results were assigned to the opposite test result interpretation than that of the corresponding comparative test results. Likewise, the comparative test equivocal results were assigned to the opposite test result interpretation than that of the corresponding SeraQuest EBV EA-D IgG Test results.
Prospectively collected and prospectively tested 477 sample results from all three sites combined are summarized in Tables 2-3.
Table 2: SeraQuest EBV EA-D IgG Test vs. Comparator Assay: Comparison by EBV Serological Status Characterization
| Comparator EBV EA-D IgG Interpretation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Positive | Equivocal | Negative | ||||||||
| EBV | ||||||||||
| Serological | ||||||||||
| Classification | SeraQuest EBV EA-D | SeraQuest EBV EA-D | SeraQuest EBV EA-D | Total | ||||||
| Pos | Equ | Neg | Pos | Equ | Neg | Pos | Equ | Neg | ||
| N | N | N | N | N | N | N | N | N | N | |
| Acute | 12 | 0 | 1 | 2 | 0 | 1 | 3 | 1 | 11 | 31 |
| EBV | 4 | 2 | 1 | 0 | 1 | 5 | 2 | 4 | 41 | 60 |
| Past Infection | 65 | 13 | 11 | 7 | 8 | 12 | 17 | 14 | 164 | 311 |
| Indeterminate | 16 | 3 | 5 | 0 | 3 | 4 | 6 | 2 | 36 | 75 |
| Overall | 97 | 18 | 18 | 9 | 12 | 22 | 28 | 21 | 252 | 477 |
5
Table 3: SeraQuest EBV EA-D IgG Test vs. Comparator Assay: Percent Agreement & Confidence Intervals by EBV Serological Status Characterization
| EBV
Serological
| Status | Positive Agreement | 95% CI | Negative Agreement | 95% CI | ||
|---|---|---|---|---|---|---|
| Acute | ||||||
| Infection | 12/14 | 85.7% | 57.2-98.2 | 11/17 | 64.7% | 38.3-85.8 |
| EBV | ||||||
| Seronegative | 4/12 | 33.3% | 9.9-65.1 | 41/47 | 87.2% | 74.3-95.2 |
| Past infection | 65/101 | 64.4% | 55.0-73.7 | 164/202 | 81.2% | 75.8-86.6 |
| Indeterminate | 16/28 | 57.1% | 37.2-75.5 | 36/44 | 81.8% | 67.3-91.8 |
| Overall | 97/155 | 62.6% | 55.0-70.2 | 252/310 | 81.3% | 76.9-85.6 |
Prospectively collected but retrospectively tested 65 specimen results from Site A are summarized in Tables 4-5.
Table 4: SeraQuest EBV EA-D IgG Test vs. Comparator Assay: Comparison by EBV Serological Status Characterization
| Comparator EBV EA-D IgG Interpretation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| EBV | ||||||||||
| Serological | ||||||||||
| Classification | Positive | Equivocal | Negative | Total | ||||||
| SeraQuest EBV EA-D | SeraQuest EBV EA-D | SeraQuest EBV EA-D | ||||||||
| Pos | Equ | Neg | Pos | Equ | Neg | Pos | Equ | Neg | ||
| N | N | N | N | N | N | N | N | N | N | |
| Acute | 32 | 0 | 0 | 1 | 1 | 1 | 2 | 3 | 10 | 50 |
| EBV | 0 | 0 | 3 | 0 | 0 | 1 | 1 | 1 | 9 | 15 |
| Overall | 32 | 0 | 3 | 1 | 1 | 2 | 3 | 4 | 19 | 65 |
Table 5: SeraQuest EBV EA-D IgG Test vs. Comparator Assay: Percent Agreement & Confidence Intervals by EBV Serological Status Characterization
| EBV
Serological
| Status | Positive Agreement | 95% CI | Negative Agreement | 95% CI | ||
|---|---|---|---|---|---|---|
| Acute | ||||||
| Infection | 32/33 | 97.0% | 84.2-99.9 | 10/16 | 62.5% | 35.4 - 84.8 |
| EBV | ||||||
| Seronegative | 0/4 | 0% | 0 - 60.2 | 9/11 | 81.8% | 48.2 - 97.7 |
| Overall | 32/37 | 86.5% | 71.2-95.5 | 19/27 | 70.4% | 49.8 - 86.2 |
In addition, test results generated by both the SeraQuest EBV EA-D IgG Test and the comparator EA-D IgG Assay relative to the actual EBV serological characterization of either acute intection, EBV seronegative or past infection, as determined by the
6
Page No.
reference EBV serology assays for EBV VCA IgG, EBV VCA IgM, and EBV EBNA-1 IgG, for the 477 prospectively collected and tested specimens and the 65 prospectively collected but retrospectively tested specimens, are presented in Tables 6-7.
Table 6: Agreement of the Comparator EBV EA-D IgG Test, and the SeraQuest EBV EA-D IgG Test, relative to the EBV Serological Classification, for the prospectively collected and tested specimens
| Prospectively Collected and Tested | ||||
|---|---|---|---|---|
| Comparator | ||||
| EBV EA-D | ||||
| IgG Test | 95% CI | SeraQuest | ||
| EBV EA-D | ||||
| IgG Test | 95% CI | |||
| Positive | ||||
| Agreement | ||||
| (Acute | ||||
| Infection) | 13/31 | |||
| 41.9% | 24.5-60.9 | 17/31 54.8% | 36.0-72.7 | |
| Negative | ||||
| Agreement | ||||
| (EBV | ||||
| Seronegative) | 47/60 | |||
| 78.3% | 65.8-87.9 | 47/60 78.3% | 65.8-87.9 | |
| Negative | ||||
| Agreement | ||||
| (Past Infection) | 195/311 | |||
| 62.7% | 57.3-68.1 | 187/311 | ||
| 60.1% | 54.7-65.6 |
Table 7: Agreements of the Comparator EBV EA-D IgG Test, and the SeraQuest EBV EA-D IgG Test, relative to the EBV Serological Classification, for the prospectively collected and retrospectively tested specimens
| Prospectively Collected and Retrospectively Tested | ||||
|---|---|---|---|---|
| Comparator | ||||
| EBV EA-D | ||||
| IgG Test | 95% CI | SeraQuest | ||
| EBV EA-D | ||||
| IgG Test | 95% CI | |||
| Positive | ||||
| Agreement | ||||
| (Acute | ||||
| Infection) | 32/50 | |||
| 64.0% | 49.2-77.1 | 35/50 70.0% | 55.4-82.1 | |
| Negative | ||||
| Agreement | ||||
| (No Infection) | 11/15 | |||
| 73.3% | 44.9-92.2 | 13/15 86.7% | 59.5-98.3 |
Cross-reactivity
The cross-reactivity study was designed to determine if samples from various disease states and other potentially interfering factors interfere with test results when tested with the SeraQuest EBV EA-D IgG Test. Specimens that were positive for various infectious diseases, heterophilic antibodies, autoimmune antibodies and antibodies against other EBV markers were tested with the SeraQuest EBV EA-D IgG Test. Samples for these
7
ATTACHMENT 7 Quest International, Inc., 8127 NW 29th Street, Doral, FL 33122
studies were selected using commercially available devices. Results can be found in Table 8.
Table 8: Cross-Reactivity
| Analytes/Condition | Number of samples | Positive or
Equivocal
SeraQuest EBV
EA-D IgG Test
Result |
|-------------------------------------------------|-------------------|----------------------------------------------------------------------|
| Cytomegalovirus
IgG | 7 | 0/7 |
| Herpes simplex
virus 1&2 IgG | 7 | 0/7 |
| Varicella zoster
virus IgG | 11 | 0/11 |
| Anti-Nuclear
Antigen antibodies | 2 | 0/2 |
| Cytoplasmatic
antigen SS-A
antibodies | 4 | 0/4 |
| Cytoplasmatic
antigen SS-B
antibodies | 4 | 0/4 |
| Extractable nuclear
antigen Sm
antibodies | 4 | 0/4 |
| Cardiolipin IgG | 6 | 0/6 |
| Rheumatoid Factor | 2 | 0/2 |
| EBV VCA IgG | 152 | 0/152 |
| EBV VCA IgM | 2 | 0/2 |
| EBV-NA antibodies | 115 | 0/115 |
| Total | 316 | 0/316 |
None of the 316 total specimens tested in the cross-reactivity studies returned positive or equivocal results in the SeraQuest EBV EA-D IgG Test.
Warning: Potential cross-reactivity of the SeraQuest EBV EA-D IgG Test with IgG antibodies to Toxoplasma gondii, Rubella virus, HIV, HAV, HBV, and HCV was not tested and determined. The user is responsible for establishing cross-reactivity performance with these infectious agents.
8
Potential Interfering Substances
The possible effects of icterus, hemolysis, hyperglycemia, hyperlipidemia and hyperproteinemia, on the results of the SeraQuest EBV EA-D IgG test, were examined. A sample panel consisted of one weak positive serum sample (close to the assay cut-off) and one negative sample was prepared. Each serum specimen was first tested without any of the additive. This served as the control representing the normal physiological concentration of each of the potential interfering substances. In addition, aliquots of each serum specimen were supplemented with 8 times the normal level of each potential interferent. These levels were selected to exceed the levels that could be present in disease state sera. The normal and the "enriched" serum specimens with bilirubin, hemoclobin, glucose, cholesterol, and gamma globulin were tested following the SeraQuest EBV EA-D IgG Instructions for Use. Results can be found in Table 9.
| ANALYTE CONCENTRATION | ||||
|---|---|---|---|---|
| NORMAL | ELEVATED | |||
| ANALYTE | POS (+) SAMPLE INDEX | NEG (-) SAMPLE INDEX | POS (+) SAMPLE INDEX | NEG (-) SAMPLE INDEX |
| BILIRUBIN | 1.5 | 0.4 | 1.5 | 0.3 |
| HEMOGLOBIN | 1.4 | 0.4 | 1.3 | 0.4 |
| GLUCOSE | 1.5 | 0.4 | 1.5 | 0.4 |
| CHOLESTEROL | 1.4 | 0.4 | 1.4 | 0.6 |
| GLOBULIN | 1.8 | 0.4 | 2.3 | 0.4 |
Table 9: SeraQuest EBV EA-D IgG Test Results with Potential Interfering Substances
No significant interference was observed in the presence of up to eight times the normal physiological concentration of each of the potential interfering substances tested with the SeraQuest EBV EA-D IgG Test. There were no false negative results for the weak positive specimen and no false positive results for the negative specimens that were encountered in the presence of each of the potential interfering substances.
Warning: While the limited amount of data presented in the study above may not demonstrate it, serum specimens with elevated levels of these interfering substances may generate erroneous results. Grossly hemolyzed, icteric or lipemic samples as well as samples containing particulate matter or exhibiting obvious microbial contamination are not recommended and should not be tested
Precision
9
A reproducibility panel of 6 members was prepared by the Quest International laboratory. One (1) of the six panel members was negative for EBV EA-D IgG. One (1) of the 6 panel members had levels of EBV EA-D IgG near the assay cut-off that was considered a high negative to equivocal sample. Four (4) of the six panel members were positive for EBV EA-D IgG. All panel members were prepared from patient samples. This panel was split into aliquots and tested at 3 different clinical sites. In addition, 1 SeraQuest human Anti-EA-D IgG positive serum control and 1 SeraQuest human Anti-EA-D IgG negative serum control were also tested. Each of the 6 panel members and the SeraQuest positive and negative controls were tested three times (x3) on each day in one run for 3 days at each of the 3 US testing sites (3 times x 3 days x 3 sites = 27 replicates per panel member and SeraQuest control). The data was analyzed for intra-assay, inter-assay and between-site reproducibility. The standard deviation (SD) and percent coefficient of variation (%CV) were also calculated. Results can be found in Table 10.
| Name of
analyte
Panel
Members | Sample
N | Mean
Index | Intra-Assay | | Inter-Assay | | Between-
Site | | Total | |
|-------------------------------------------------------|-------------|---------------|-------------|------|-------------|------|------------------|------|-------|------|
| | | | SD | %CV | SD | %CV | SD | %CV | SD | %CV |
| SeraQuest
Positive
Serum
Control | 27 | 1.7 | 0.05 | 3.1 | 0.13 | 8.0 | 0.32 | 19.3 | 0.14 | 8.0 |
| SeraQuest
Negative
Serum
Control | 27 | 0.4 | 0.01 | 4.1 | 0.04 | 9.1 | 0.07 | 21.0 | 0.03 | 8.4 |
| High
negative
to
equivocal
(Near
C.O.) | 27 | 0.7 | 0.04 | 5.7 | 0.07 | 9.5 | 0.10 | 14.2 | 0.03 | 4.2 |
| Negative | 27 | 0.2 | 0.05 | 18.2 | 0.06 | 23.1 | 0.12 | 46.7 | 0.04 | 14.0 |
| Positive 1 | 27 | 1.7 | 0.08 | 4.2 | 0.09 | 5.8 | 0.40 | 23.8 | 0.19 | 10.5 |
| Positive 2 | 27 | 1.3 | 0.07 | 5.2 | 0.07 | 5.9 | 0.26 | 19.5 | 0.11 | 7.9 |
| Positive 3 | 27 | 1.3 | 0.04 | 3.0 | 0.08 | 6.6 | 0.26 | 20.5 | 0.12 | 8.9 |
| Positive 4 | 27 | 1.7 | 0.09 | 4.7 | 0.24 | 14.1 | 0.40 | 24.1 | 0.16 | 9.2 |
Table 10: Reproducibility (Values were calculated from the SeraQuest index values.)
10
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/10/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three stripes forming its body and wings. The eagle is enclosed within a circular border, with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the circumference of the circle.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Dr. David Kiefer President Quest International, Inc. 8127 N. W. 29th Street Doral, FL 33122
JUN ~ 8 2009
Re: K091260
Trade/Device Name: SeraQuest EBV EA-D IgG Test Regulation Number: 21 CFR 866.3235 Regulation Name: Multiple antibodies immunological test system Regulatory Class: Class I Product Code: LSE Dated: April 3, 2009 Received: April 29, 2009
Dear Dr. Kiefer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations , affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
11
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Sally attaym
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
12
Indication for Use
510(k) Number: K091260
Device Name: SeraQuest EBV EA-D IgG
Indication For Use:
The SeraQuest EBV EA-D IgG test is for the qualitative detection of human IgG antibodies to Epstein-Barr virus early antigen diffuse (EA-D) in human serum by enzyme immunoassay. This assay uses a 28 kd E. coli expressed recombinant Epstein-Barr virus early antigen. When performed in conjunction with other EBV serological tests, this assay can be used as an aid in the laboratory diagnosis of EBV infectious monomucleosis in patients with signs and symptoms of EBV infectious mononucleosis. For In Vitro Diagnostic Use Only.
Assay performance characteristics have not been established for neonatal, immunocompromised populations, cord blood, infants or pre-transplant patients. Assay performance characteristics have not been established for the diagnosis of nasopharyngeal carcinoma, Burkitt's lymphoma, and other EBV-associated lymphomas.
Prescription Use X And/Or (21 CFR Part 801 Subpart D)
Over the Counter Use 11.000 (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Uwe Schef
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K091260